Drug Database
SO

somatotropin (somatropin, Schwarz / Nutropin AQ v1.1 / Protropin II)

✓ Approved

Roche · GHR · 重组蛋白

什么是 somatotropin?

somatotropin 是一种重组蛋白,由Roche研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名somatropin, Schwarz, Nutropin AQ v1.1, Protropin II
公司Roche
药物类别重组蛋白
分子靶点GHR
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved

作用机制

分子靶点

somatotropin 作用于 1 个分子靶点:

GHRgrowth hormone receptor (GHBP, GHIP)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

somatotropin 针对 4 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Endocrine disordersGrowth hormone deficiency✓ Approved
Congenital, familial and genetic disordersSex chromosome abnormality✓ Approved
Congenital, familial and genetic disordersOsteochondrodysplasia✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved

相关研究文献

PubMedJournal of animal science2026-11-16

Effects of combining increased lysine (protein) supply and exogenous somatotropin on mammary development in late gestation gilt.

Farmer Chantal C, Dufresne Alexandra J AJ, Hovey Russell C RC, Huber Lee-Anne LA

The goal of this project was to determine the impacts of increased dietary lysine (protein) and exogenous porcine somatotropin (pST) during late gestation, either separately or in combination, on mammary development of gilts. On day 85 of gestation, gilts were assigned to one of four groups: 1) fed SID lysine at estimated NRC requirement with daily injections of sterile water (CTL, control, n =17), 2) fed SID lysine at 40% above requirement via additional soybean meal and receiving daily injections of sterile water (LYS, n = 18), 3) fed SID lysine at estimated NRC requirement and receiving daily I.M. injections of 5 mg of pST (pST, n =19), or 4) fed SID Lys at 40% above requirement via additional soybean meal and receiving daily I.M. injections of 5 mg of pST (LYSpST, n = 17). The pST was diluted in 1 mL of sterile water. Dietary lysine treatment started on day 85 of gestation and pST treatment started on day 90 of gestation. The lysine treatment started earlier to maximize its potential effect, whereas the pST available did not allow for that. Both treatments lasted until slaughter on day 110, at which time mammary glands were collected and dissected. All gilts were weighed and had their backfat thickness measured at mating and on days 84 and 110 of gestation. Injections with pST increased mammary development leading to more parenchymal tissue (P < 0.001) that contained less percent fat (P < 0.0001), more percent protein, and greater concentrations of DNA and RNA (P < 0.0001), alongside increased alveolar expansion (P < 0.05). Supplementary lysine did not reproduce a previously-reported positive effect on mammary development. This divergence could be due to a lighter BW of gilts at the onset of treatment in the previous study, whereby supplementary lysine would have a beneficial effect only in lighter gilts. These data precluded any determination of whether combining supplementary dietary lysine and injections of pST in late-pregnant gilts act synergistically to enhance mammary development, whereas pST was effective in significantly improving both mammary parenchymal mass and composition.

PMID 43037116
阅读全文 →
PubMedResearch square2026-11-06

Second-generation tau PET tracer in situ binding assessed with fluorescence imaging.

Antic Aleksandra A, Dreos Ambra A, Lashley Tammaryn T, Yo-Ap Stephen Yong SY et al.

Brain positron emission tomography (PET) imaging is a valuable tool which allows visualization of the pathological structures inside the living patients' brains. While amyloid-β PET tracers have been in use with Alzheimer's disease patients in clinics, tau PET tracers have still not entered the clinical routine. Second-generation tau PET tracers have been developed with the aim to overcome the limitations of the first-generation tau PET tracers, such as low sensitivity and off-target binding. However, the detailed pathological characterization of these tracers' binding is still needed for fully understanding their potential as accurate markers of pathogenic tau. Herein, we focused on the second-generation tau PET tracer Genentech Tau Probe 1 ([18F]GTP1) and made use of the fluorescent properties of its non-radioactive unlabeled variant GTP1 for correlative fluorescence microscopy. The results show that GTP1 binds to tau tangles and neuropil threads (NPTs), but not amyloid-β plaques. Importantly, our results indicate that there is a strong correlation between the fluorescent GTP1 signal and the [18F]GTP1 signal detected with autoradiography, which is currently the standard way of studying the tau PET tracer binding in situ. Together, this data shows the robust application of a non-radioactive tau PET tracer in binding studies in post-mortem tissue and sheds new light on the tau binding properties of GTP1.

PMID 42990816
阅读全文 →
PubMedLancet regional health. Americas2026-10-06

Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study.

Lee Seungwon S, Scheu Raphael R, Enkhtsetseg Nomin N, Hill Justin J et al.

Pivotal trials for ocrelizumab in multiple sclerosis (MS) excluded adults >55 years old. This study aimed to compare rates of infection and infection-related hospitalization between ocrelizumab-treated and unexposed older adults with MS. A retrospective cohort study was performed, analyzing the electronic medical records, June 2017-January 2026, at the Massachusetts General Hospital, comparing 800 older adults with MS who received at least 600 mg of ocrelizumab IV to 800 older adults who never received B-cell depleting therapies. Infection and related hospitalization rates were modeled using inverse probability of treatment weighting and negative binomial regression with person-time offsets. Among 1600 adults (n = 1111, 69.4% female; n = 1496, 93.5% White; median ages 64 (range 55-88) for ocrelizumab and 67 years (range 55-98) for unexposed), median follow-up was 3.5 vs. 8.2 years. There were 429 infection-related hospitalizations (164 ocrelizumab, 265 unexposed), 10 infection-associated deaths (2 ocrelizumab, 8 unexposed), and 4538 infections (1597 ocrelizumab, 2941 unexposed). After adjustment, ocrelizumab was associated with a higher infection-associated hospitalization rate (IRR 1.67; 95% CI 1.15-2.43; p = 0.008) and infections (IRR 1.42; 95% CI 1.20-1.68; p < 0.001). Higher disability and comorbidity independently increased the risk of both outcomes. Female sex was associated with a higher infection risk (IRR 1.36, 95% CI 1.12-1.64, p = 0.002), driven mostly by urinary tract infections, which accounted for 91.46% of the observed sex difference. In adults aged ≥55 years with MS, ocrelizumab was associated with higher rates of infection-related hospitalization and infections. Findings support individualized risk-benefit discussion, especially regarding UTIs in older patients of female sex, dedicated UTI monitoring and prevention protocols for older ocrelizumab-treated patients, and inclusion of this age group in future clinical trials. Investigator-initiated grant from Genentech.

PMID 42834886
阅读全文 →
PubMedToxicological sciences : an official journal of the Society of Toxicology2026-10-05

A multiparametric in vitro strategy for small molecule drug-induced liver injury risk mitigation in early drug development.

Norona Leah M LM, Melnikov Fjodor F, Kiyota Tomomi T, Lawson Christopher C et al.

Drug-induced liver injury (DILI) remains a major cause of preclinical and clinical attrition, reflecting persistent gaps in the predictive translation of preclinical safety data to human outcomes. To address these gaps, we established a refined multiparametric framework for early DILI risk prediction using a balanced reference set of 170 drugs with established clinical outcomes. Thirty physicochemical, mechanistic endpoints, and exposure-related features were systematically evaluated to identify high-specificity predictors of intrinsic DILI risk. Cytotoxicity in primary human hepatocytes and human liver microtissues, mitochondrial toxicity (i.e. mitotoxicity), and bile salt export pump inhibition were identified as top predictive features. Incorporation of clinical exposure data to derive margins of safety substantially improved assay performance, emphasizing the importance of exposure normalization. A multiparametric, flag-based hazard framework integrating ≥2 hazard flags achieved 98% specificity and a positive likelihood ratio of 18, providing a pragmatic approach for early compound triage and confidence in early decision-making. Random Forest models further enhanced predictive performance, identifying exposure, predicted lipophilicity (e.g. cLogD), mitotoxicity, cytotoxicity, and hepatic clearance as major contributors to DILI risk, with exposure-informed models achieving a balanced accuracy of 0.72. Application of the framework to contemporary Genentech portfolio molecules demonstrated translational utility in refining risk categorization, particularly for compounds with borderline or 0-1 hazard flags. Collectively, this work establishes a mechanistically informed and machine learning-enabled platform that combines interpretability, specificity, and practicality to guide safer molecule design in drug discovery and reduce hepatotoxicity-related attrition in clinical development.

PMID 42830472
阅读全文 →
PubMedThe New England journal of medicine2026-09-30

Giredestrant plus Everolimus in Advanced Breast Cancer.

Mayer Erica L EL, Tolaney Sara M SM, Martín Miguel M, Vidal Gregory A GA et al.

Giredestrant and everolimus target the estrogen receptor (ER) pathway and the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway, respectively, which are implicated in endocrine-therapy resistance. In this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who had disease progression or recurrence after receipt of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor plus endocrine therapy. Patients were assigned, in a 1:1 ratio, to receive giredestrant plus everolimus (each given orally) or standard endocrine therapy (i.e., exemestane, fulvestrant, or tamoxifen) plus everolimus. The primary end point was investigator-assessed progression-free survival, evaluated first among patients with ESR1-mutated tumors and then in the overall trial population. Overall, 373 patients underwent randomization, with 183 assigned to the giredestrant-everolimus group and 190 to the standard therapy-everolimus group. Among 207 patients with ESR1-mutated tumors, the median progression-free survival was 10.0 months with giredestrant-everolimus and 5.5 months with standard therapy-everolimus (hazard ratio for disease progression or death, 0.38; 95% confidence interval [CI], 0.27 to 0.54; P<0.001). In the overall population, the median progression-free survival was 8.8 months with giredestrant-everolimus and 5.5 months with standard therapy-everolimus (hazard ratio, 0.56; 95% CI, 0.44 to 0.71; P<0.001). Adverse events occurred in 98.9% of patients who received giredestrant-everolimus and in 96.8% of those who received standard therapy-everolimus. The most common adverse events were stomatitis (in 47.3% of giredestrant-everolimus recipients and 48.9% of standard therapy-everolimus recipients), diarrhea (in 26.9% and 22.6%, respectively), and anemia (in 23.6% and 21.0%). An all-oral giredestrant-everolimus regimen led to significantly longer progression-free survival than standard endocrine therapy-everolimus among patients with ER-positive, HER2-negative advanced breast cancer who had received a CDK4/6 inhibitor previously, mainly in patients with ESR1-mutated tumors. The incidence of adverse events was similar in the two groups. (Funded by Genentech; evERA Breast Cancer ClinicalTrials.gov number, NCT05306340.).

PMID 42814929
阅读全文 →
PubMedLancet (London, England)2026-09-06

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.

Daly Megan E ME, Simone Charles B CB, Redman Mary W MW, Hsieh Ming-Hui MH et al.

Stereotactic body radiation therapy (SBRT) is the standard of care for early-stage, medically inoperable non-small-cell lung cancer (NSCLC). We aimed to test the addition of neoadjuvant, concurrent, and adjuvant atezolizumab with SBRT for early-stage NSCLC. In this multicentre, open-label, phase 3, randomised controlled trial, eligible patients from 146 institutions across the USA who had T1-T3N0M0 NSCLC ≤7 cm, and were medically inoperable or declined surgery, and had at least one risk factor suggestive of increased risk of recurrence, were included in the study. Patients underwent open-label equal and stratified randomisation to SBRT over three to eight fractions with or without up to eight cycles of neoadjuvant, concurrent, and adjuvant atezolizumab 1200 mg intravenously every 21 days for up to eight cycles, with SBRT initiated with cycle three. The primary objective was to compare overall survival between the two groups. The group sequential design included four interim analyses. Target accrual was 480 patients (432 eligible). The trial is registered with ClinicalTrials.gov (NCT04214262) and is closed to new participants. Between March 25, 2020, and Sept 9, 2024, 417 patients were enrolled and randomly assigned to atezolizumab plus SBRT (n=210) or SBRT alone (n=207). 402 were eligible and made up the modified intention-to-treat population (201 per group). The median age was 72·8 years (IQR 67·4-78·4), 218 (54%) of 402 participants were female, and 184 (46%) were male. Accrual closed at the first interim analysis of all randomly assigned participants for futility with 76 progression-free survival (PFS) events and 41 deaths among 400 eligible participants (200 per group). An updated analysis was performed with 140 PFS events, 92 deaths, and a median of 24·8 months (range 0·1-64·9; IQR 18·6-36·0) of follow-up among living patients. The overall survival hazard ratio was 1·04 (95% CI 0·69-1·58; one-sided p=0·58). Estimated 2-year overall survival was 82% in both groups (95% CI 75-87). Grade 3 or higher adverse event rates were 12% with atezolizumab plus SBRT and 3% with SBRT. Two grade 5 respiratory events occurred in the atezolizumab plus SBRT group. In the first fully reported phase 3 cooperative group trial to assess immunotherapy in inoperable early-stage NSCLC, we observed no improvement in overall survival with atezolizumab plus SBRT, and more grade 3 or higher adverse events were reported with atezolizumab combined with SBRT. US National Institutes of Health, US National Cancer Institute, and Genentech.

PMID 42702214
阅读全文 →

注册免费账户还可查看另外 3680 篇文献

免费注册查看全部文献 →

了解更多somatotropin